Bernard Reculeau
Keine laufenden Positionen mehr
Profil
Bernard Reculeau served as Chairman at CIS Bio International SA. He was a Director at Theratechnologies, Inc. from 2005 to 2011.
From 2010 to 2014, he served as Director at Neurokin SA. He was a Member-Management Team at Ion Beam Applications SA. He also served as Senior Vice President at Aventis, Inc. Mr. Reculeau was President at Cisbio Bioassays SAS in 2009.
He was a General Manager at Rhone-Poulenc Rorer, Inc. and Senior Vice President & General Manager at Rhone-Poulenc Rorer SA. Mr. Reculeau received his undergraduate degree from Sciences Po in 1974 and from Ecole Nationale d'Administration in 1977.
Ehemalige bekannte Positionen von Bernard Reculeau
| Unternehmen | Position | Ende |
|---|---|---|
Neurokin SA
 Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Direktor/Vorstandsmitglied | 11.03.2014 |
Cisbio Bioassays SAS
 Cisbio Bioassays SAS Medical SpecialtiesHealth Technology Cisbio Bioassays SAS develops immunoassays and other related pharmaceutical products. The firm specializes in anti-bodies, vitro diagnostics, and medication for various diseases such as cancer and neurodegenerative disorder. The company was founded in 1986 and is headquartered in Codolet, France. | Präsident | 01.01.2009 |
| Rhone-Poulenc Rorer SA | Corporate Officer/Principal | - |
Rhone-Poulenc Rorer, Inc.
 Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Corporate Officer/Principal | - |
| Aventis, Inc. | Corporate Officer/Principal | - |
Ausbildung von Bernard Reculeau
| Sciences Po | Undergraduate Degree |
| Ecole Nationale d'Administration | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ION BEAM APPLICATIONS, SA | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
| Aventis, Inc. | |
Cisbio Bioassays SAS
Cisbio Bioassays SAS Medical SpecialtiesHealth Technology Cisbio Bioassays SAS develops immunoassays and other related pharmaceutical products. The firm specializes in anti-bodies, vitro diagnostics, and medication for various diseases such as cancer and neurodegenerative disorder. The company was founded in 1986 and is headquartered in Codolet, France. | Health Technology |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Health Technology |
CIS Bio International SA
 CIS Bio International SA Pharmaceuticals: MajorHealth Technology CIS Bio International SA engages in the distribution of radiopharmaceuticals for diagnosis and therapy. The company is headquartered in Saclay, France. | Health Technology |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
| Rhone-Poulenc Rorer SA |